# The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab

> **NCT07688239** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tiziana Life Sciences LTD** · enrollment: 44 (estimated)

## Conditions studied

- ALS (Amyotrophic Lateral Sclerosis)
- ALS - Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** Foralumab Nasal
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07688239
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-25
- **Primary completion:** 2027-07
- **Final completion:** 2027-11
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688239, "The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*